ProPhase Labs, Inc. Accrued Liabilities for Commissions, Expense and Taxes
ProPhase Labs, Inc. (PRPH) had Accrued Liabilities for Commissions, Expense and Taxes of $0 as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Financial Services
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2024-03-29
- 2023-12-31: Accrued Liabilities for Commissions, Expense and Taxes $0.00.
- 2022-12-31: Accrued Liabilities for Commissions, Expense and Taxes $1.09M.
- 2022-09-30: Accrued Liabilities for Commissions, Expense and Taxes $2.45M.
- 2022-06-30: Accrued Liabilities for Commissions, Expense and Taxes $849.00K.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2022-12-31 | $1.09M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.45M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $849.00K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.29M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $1.28M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.05M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $639.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $3.49M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $461.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |